Biomarker Testing Is Connecting Drug Development With More Targeted Treatment
Personalized medicine increasingly depends on identifying which patients are most likely to benefit from a particular therapy. Companion diagnostics help address this requirement by detecting biomarkers associated with treatment response or safety.
The companion diagnostics development market is projected to grow from approximately USD 779 million in 2026 to USD 1.80 billion by 2035, representing a CAGR of 9.7%.
Companion diagnostic development involves several stages, including biomarker identification, assay development, analytical validation, clinical validation and manufacturing.
NGS currently represents an important analytical technology because of its ability to analyze multiple genetic markers from relatively small samples. PCR, immunohistochemistry and flow cytometry are also widely used.
Oncology remains the dominant therapeutic area because many cancer treatments depend on identifying specific molecular characteristics of tumors.
The regulatory environment is another major driver. Drug developers increasingly need to demonstrate that their therapies can be used safely and effectively in the appropriate patient population.
Outsourcing has therefore become common. More than 155 contract service providers are captured in the current landscape, offering services across different stages of CDx development.
Liquid biopsy is also expanding the field by enabling biomarker assessment through blood-based samples in selected applications.
As targeted therapies become more common, companion diagnostics are likely to become increasingly integrated with pharmaceutical development programs rather than being treated as separate diagnostic products.
For more information on the Companion Diagnostics Development Market, visit:
https://www.rootsanalysis.com/reports/companion-diagnostics-services/297.html
Comments